Veterinary Medicines

MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS

Authorised
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
Download as PDF

Product identification

Medicine name:
MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS
Active substance:
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
    9.00
    Organisms
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, Inactivated
    9.00
    Organisms
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    4.00
    tissue culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain Lederle, Live
    4.00
    tissue culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain Cornell 780916, Live
    6.00
    tissue culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • Spanish Agency For Medicines And Medical Devices
Authorisation number:
  • 1405 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 13/09/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 13/09/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 13/09/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."